WAVEMAN · COMPANY

RCUS · Arcus Biosciences, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

RCUS

Name: Arcus Biosciences, Inc. (RCUS) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Arcus Biosciences, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001724521

FORM 144 · 4☆ WATCH

INSIDER NET · 180D

-$3.3M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

137

13F, latest reported quarter

REVENUE GROWTH

-35.3%

XBRL, annual

NET MARGIN

-1069.7%

CONVERSIONS · 180D

codes C/M, not in net · $131.3K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$3.3M over 180 days

-$3.0M over 90 days

below 74% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

137 funds added or opened last quarter

more than 76% of Pharma & Biotech

REVENUE

-35.3% year over year

below 79% of Pharma & Biotech

MARGIN

-1069.7% net margin

below 89% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$3.3M across 3 people in 180 days.

137 funds added or opened positions in the latest 13F quarter, of 233 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +176.1%

+176.1%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $3.3M sold by insiders over 180 days, 137 funds added last quarter, $3.0M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Arcus Biosciences, Inc. insiders sold a net $3.3M of stock across 136 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Azoy Alexander

Chief Accounting Officer

SELL

2026-08-21

2,827.0

$84.8K

Jaen Juan C.

President

SELL

2026-07-10

19,799.0

$566.4K

Jaen Juan C.

President

SELL

2026-07-10

268.0

$7.9K

Jaen Juan C.

President

SELL

2026-07-09

48,502.0

$1.5M

Jaen Juan C.

President

SELL

2026-06-24

6,431.0

$190.7K

136 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 131 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

GILEAD SCIENCES, INC.

31,424,760.0 sh

$968.8M

BlackRock, Inc.

16,416,249.0 sh

$506.1M

STATE STREET CORP

6,029,484.0 sh

$185.9M

WELLINGTON MANAGEMENT GROUP LLP

5,895,448.0 sh

$181.8M

MONTANOVA CAPITAL, LLC

4,776,423.0 sh

$147.3M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

ALEXANDER AZOY

FILED 2026-08-21

$83.5K

Juan Jaen

FILED 2026-07-09

$749.0K

Juan Jaen

FILED 2026-06-24

$1.4M

Juan Jaen

FILED 2026-06-22

$680.8K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

iShares Genomics Immunology and Healthcare ETF

$3.4M POSITION · AS OF 2026-04-30

2.1%

Nomura Healthcare Fund

$8.2M POSITION · AS OF 2026-03-31

1.2%

Invesco S&P SmallCap Health Care ETF

$1.4M POSITION · AS OF 2026-02-28

1.0%

Invesco Dorsey Wright Healthcare Momentum ETF

$1.1M POSITION · AS OF 2026-04-30

0.9%

Virtus Biotech Clinical Trials Etf

$326.9K POSITION · AS OF 2026-04-30

0.9%

State Street(R) SPDR(R) S&P(R) Biotech ETF

$46.7M POSITION · AS OF 2026-03-31

0.6%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 32 registered trials, 10 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

6 ACTIVE

Phase 2

2 ACTIVE

Phase 3

2 ACTIVE

Multi-phase

0 ACTIVE

What changed recently

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Che

2026-09-04 · Completion moved 2026-08 → 2026-08-28

Phase 3

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Che

2026-09-04 · Active Not Recruiting → Completed

Phase 3

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Dr. Rosen

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$9.7M

$17.7M

$3.6M

-10%

-12%

2024

$7.3M

$4.8M

$2.8M

+47%

-5%

2023

$10.1M

$7.5M

$4.2M

+94%

-6%

2022

$9.0M

-$2.1M

$4.2M

+105%

-12%

2021

$9.5M

$14.6M

$5.9M

+301%

+18%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$33.0M	$51.0M	$37.0M	$38.0M
OPERATING INCOME	$-386.0M	$-330.0M	$-340.0M	$-280.0M
NET INCOME	$-353.0M	$-283.0M	$-307.0M	$-267.0M
EPS (DILUTED)	-3.29	-3.14	-4.15	-3.71
OPERATING CASH FLOW	$-482.0M	$-170.0M	$-306.0M	$438.0M
CASH	$222.0M	$150.0M	$127.0M	$206.0M
LONG-TERM DEBT	$99.0M	$48.0M	$0	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE